SAN DIEGO, CA, USA I June 11, 2025 I Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo ...

BARCELONA, Spain I June 11, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...

BASEL, Switzerland I June 12, 2025 I Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I June 11, 2025 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company ...

Significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, measures of disease activity and quality of life at Week 16 ...

COPENHAGEN, Denmark I June 12, 2025 I SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for ...

In the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label HALOS study, ION582 provided consistent and encouraging clinical improvement on all functional domains including ...

INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...

Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year ...

STRASBURG, France and CHARLEROI, Belgium I June 11, 2025 I Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic ...

CATANIA, Italy I June 10, 2025 I SIFI, a leading international ophthalmic company, today announced that its shareholders have signed an agreement, subject to ...

BERLIN, Germany & CAMBRIDGE, MA, USA I June 11, 2025 I Bayer and the Broad Institute today announced that they have extended their research collaboration ...